Challenge of studies on the development of new Zn complexes (Zn(opt)2) to treat diabetes mellitus

Abstract

The number of worldwide patients suffering from diabetes mellitus (DM) is forecasted to increase over time. The development of compounds without severe side effects for type 2 DM is required not only to treat DM but also to improve the quality of life (QOL) of patients. In this paper, we have described the synthesis of novel first transition metal complexes with S₂O₂ coordination mode and discussed their anti-diabetic activities. Di(1-oxy-2-pyridinethiolato)Zn complex (Zn(opt)₂) with Zn(S₂O₂) coordination mode displayed higher insulin mimetic with anti-diabetic activity, compared to the ZnCl₂ or clinically used medicine (pioglitazone). In addition, Zn(opt)₂ improved the insulin and adiponectine levels in the plasma. The gastrointestinal absorption of the Zn complex was found to be higher than that of ZnCl₂. Based on these results, we propose that the Zn(opt)₂ complex with Zn(S₂O₂) coordination mode is a novel candidate for the treatment of type 2 DM; through oral administration.